<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">JOHNSON, BEVERLY K.</style></author><author><style face="normal" font="default" size="100%">BAHÇE-ALTUNTAŞ, ASENA</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Dr. Johnson and Dr. Bahçe-Altuntaş reply</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Rheumatology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">876-876</style></pages><doi><style  face="normal" font="default" size="100%">10.3899/jrheum.171473</style></doi><volume><style face="normal" font="default" size="100%">45</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">We appreciate the interest in our editorial1 regarding Dr. Stamp’s study of joint replacement rates in New Zealand2, as expressed by Dr. Boers3. We are happy to have opened an international dialogue regarding barriers to access to biologic disease-modifying antirheumatic drugs (bDMARD). We agree with Dr. Boers that the high price of bDMARD is a … Address correspondence to Dr. B.K. Johnson, Jacobi/NCB, Rheumatology, 1400 Pelham Parkway, South Building 1, Suite 306, New York, New York 10461, USA. E-mail: beverly.johnson06{at}gmail.com</style></abstract></record></records></xml>